Lexicon Pharmaceuticals (LXRX) Other Operating Expenses (2014 - 2026)

Lexicon Pharmaceuticals (LXRX) has 12 years of Other Operating Expenses data on file, last reported at $108000.0 in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $108000.0, up 260.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $352000.0 (down 42.76% YoY), and the FY2025 annual result was $274000.0, down 55.52% from the prior year.
• Other Operating Expenses retreated to $108000.0 in Q1 2026 per LXRX's latest filing, from $201000.0 in the prior quarter.
• Over five years, Other Operating Expenses peaked at $10.7 million in Q2 2022 and troughed at $7000.0 in Q3 2023.
• A 5-year average of $1.4 million and a median of $70500.0 in 2023 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2023 and 2024: Other Operating Expenses sank 99.93% in 2023, then jumped 1975.0% in 2024.
• A 5-year view of Other Operating Expenses shows it stood at $10.7 million in 2022, then plunged by 99.34% to $70000.0 in 2023, then surged by 397.14% to $348000.0 in 2024, then sank by 42.24% to $201000.0 in 2025, then sank by 46.27% to $108000.0 in 2026.
• Business Quant data shows LXRX's Other Operating Expenses at $108000.0 in Q1 2026, $201000.0 in Q4 2025, and $10000.0 in Q3 2025.